Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 103,900 shares, a growth of 76.1% from the November 30th total of 59,000 shares. Currently, 3.6% of the company’s shares are sold short. Based on an average daily trading volume, of 2,220,000 shares, the days-to-cover ratio is presently 0.0 days.

Senti Biosciences Trading Down 5.3 %

Shares of NASDAQ:SNTI traded down $0.22 during trading on Friday, reaching $3.92. 73,351 shares of the company traded hands, compared to its average volume of 774,802. Senti Biosciences has a 52-week low of $1.52 and a 52-week high of $16.94. The firm has a market capitalization of $17.99 million, a price-to-earnings ratio of -0.25 and a beta of 2.69. The business’s fifty day moving average is $3.45 and its 200-day moving average is $2.89.

Wall Street Analyst Weigh In

Separately, Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Senti Biosciences in a research note on Monday, December 2nd.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.